#1 Clinical Trials Search in Europe

Larotrectinib Sulfate

Larotrectinib Sulfate, also known as LOXO-101, is an innovative targeted therapy being studied in clinical trials for patients with advanced solid tumors, lymphomas, and leukemias that have specific genetic alterations called TRK fusions. These trials aim to evaluate how well larotrectinib works in shrinking tumors and improving outcomes for patients whose cancers have not responded to standard treatments. The drug works by blocking TRK proteins that drive cancer growth in tumors with NTRK gene fusions.

Table of Contents

What is Larotrectinib?

Larotrectinib Sulfate, also known by its brand name Vitrakvi, is a targeted cancer therapy drug. It’s also referred to by several other names in scientific literature, including ARRY 470 Sulfate, LOXO 101 Sulfate, and LOXO-101 Sulfate[2][4]. This medication is part of a new generation of cancer treatments that focus on specific genetic changes in cancer cells rather than attacking all rapidly dividing cells like traditional chemotherapy.

How Does Larotrectinib Work?

Larotrectinib is designed to target a specific genetic alteration in cancer cells. It works by blocking enzymes called TRK (tropomyosin receptor kinase) proteins. These proteins are produced when certain genes, known as NTRK genes, fuse or join with other genes. This fusion can lead to uncontrolled cell growth and cancer. By blocking the TRK proteins, Larotrectinib may stop the growth of tumor cells[1][2].

What Conditions Does Larotrectinib Treat?

Larotrectinib is used to treat a variety of cancers that have a specific genetic feature called an NTRK gene fusion. These cancers can occur in different parts of the body and include:

  • Solid tumors: These are cancers that form solid masses in the body, such as in the lungs, breast, or colon[1].
  • Locally advanced cancers: These are cancers that have spread from where they started to nearby tissue or lymph nodes[1].
  • Metastatic cancers: These are cancers that have spread to other parts of the body[1].
  • Infantile fibrosarcoma: A rare type of cancer that occurs in infants and young children[2].
  • Central nervous system tumors: Cancers that occur in the brain or spinal cord[2].
  • Relapsed or refractory acute leukemia: Blood cancers that have come back after treatment or do not respond to initial treatment[2].

It’s important to note that Larotrectinib is typically used when the cancer has progressed after other treatments or when there is no satisfactory alternative treatment option[3].

How is Larotrectinib Administered?

Larotrectinib is taken orally (by mouth) in the form of a pill or liquid. It’s usually taken twice a day. In some cases, especially for patients who can’t swallow pills, it can be given through a nasogastric tube (a tube that goes through the nose into the stomach) or a gastric tube (a tube that goes directly into the stomach)[2][3].

The treatment is typically given in cycles, with each cycle lasting 28 days. Patients may continue taking Larotrectinib for up to 26 cycles (about 2 years) as long as the cancer doesn’t get worse and the side effects are manageable[2][3].

Clinical Trials and Research

Larotrectinib has been and continues to be studied in various clinical trials. These studies aim to understand how well the drug works for different types of cancers and in different patient populations. Some key aspects of these trials include:

  • Objective Response Rate (ORR): This measures how many patients’ tumors shrink or disappear after treatment. In some trials, researchers are looking at whether Larotrectinib can shrink tumors enough to make surgery possible[1][2].
  • Duration of Response (DoR): This looks at how long the cancer stays controlled after it responds to treatment[1].
  • Progression-Free Survival (PFS): This measures how long patients live without their cancer getting worse[1].
  • Overall Survival (OS): This looks at how long patients live overall after starting treatment[1].
  • Safety and Side Effects: Researchers are carefully monitoring any side effects or safety concerns related to the medication[1][2].

Some trials are also looking at using Larotrectinib before surgery (called neoadjuvant therapy) to see if it can shrink tumors and make surgery easier or more effective[2].

Potential Side Effects

As with all medications, Larotrectinib can cause side effects. In clinical trials, researchers are carefully monitoring patients for any adverse reactions. Common side effects may include fatigue, nausea, dizziness, and constipation. More serious side effects are possible but less common. It’s important for patients to discuss potential side effects with their healthcare provider[1][2].

Larotrectinib represents a significant advancement in targeted cancer therapy. By focusing on specific genetic changes in cancer cells, it offers hope for patients with various types of cancers that have not responded to other treatments. As research continues, we may learn even more about how to use this medication effectively to help cancer patients.

Aspect Details
Drug Name Larotrectinib Sulfate (LOXO-101)
Target TRK proteins in cancers with NTRK gene fusions
Administration Oral (tablets/liquid), twice daily; sometimes via NG or G-tube
Cancer Types Advanced solid tumors, lymphomas, leukemias with TRK fusions
Key Outcomes Measured Objective response rate, progression-free survival, overall survival, duration of response
Safety Monitoring Adverse events, focusing on grade 3 or higher toxicities
Additional Assessments Tumor biopsies, blood samples, imaging (CT, MRI, PET scans)
Special Populations Includes pediatric patients in some trials
Treatment Duration Up to 2 years in absence of disease progression or unacceptable toxicity

FAQ

  • What types of cancers is larotrectinib being studied for? Larotrectinib is being studied for a wide range of advanced solid tumors, lymphomas, and leukemias that have TRK fusions. This includes locally advanced or metastatic solid tumors, infantile fibrosarcoma, central nervous system tumors, and relapsed/refractory acute leukemias with NTRK gene fusions.
  • How is larotrectinib administered? Larotrectinib is given orally (by mouth) in the form of tablets or liquid, usually twice daily. In some trials, it can also be administered via nasogastric tube or gastric tube for patients who cannot take it orally.
  • What are TRK fusions and how does larotrectinib target them? TRK fusions are genetic alterations where the NTRK genes (NTRK1, NTRK2, or NTRK3) fuse with other genes, leading to abnormal TRK proteins that drive cancer growth. Larotrectinib works by specifically blocking these abnormal TRK proteins, potentially stopping or slowing down cancer growth.
  • What are the main goals of the clinical trials studying larotrectinib? The main goals include determining the overall response rate (how many patients' tumors shrink), assessing progression-free survival, evaluating overall survival, measuring the duration of response, and monitoring the safety and side effects of the treatment.
  • Are there any specific side effects being monitored in these trials? While specific side effects vary between trials, researchers are generally monitoring for any adverse events, with a focus on grade 3 or higher toxicities. Some trials are also evaluating the impact on heart function through echocardiograms or other cardiac tests.

Ongoing Clinical Trials on Larotrectinib Sulfate

  • Study of Larotrectinib and Drug Combination for Children with Newly Diagnosed High-Grade Glioma with NTRK Fusion

    Recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany

  • Study on Larotrectinib for Treating Children with Advanced Solid Tumors with NTRK Fusion

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Czechia Denmark France Germany Ireland Italy +3

  • Study on How Larotrectinib Works in Adults with Solid Tumors with NTRK Gene Fusion

    Not recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    Denmark France Germany Portugal Spain Sweden

Glossary

  • TRK fusion: A genetic alteration where NTRK genes (NTRK1, NTRK2, or NTRK3) combine with other genes, creating abnormal proteins that can drive cancer growth.
  • Larotrectinib Sulfate: A targeted therapy drug that inhibits TRK proteins, used to treat cancers with NTRK gene fusions.
  • NTRK gene: Genes (NTRK1, NTRK2, NTRK3) that normally help regulate nervous system development but can drive cancer growth when fused with other genes.
  • Objective response rate (ORR): The proportion of patients whose tumors shrink (partial response) or disappear (complete response) after treatment.
  • Progression-free survival (PFS): The length of time during and after treatment that a patient lives without the cancer growing or spreading.
  • Overall survival (OS): The length of time from the start of treatment that patients are still alive.
  • Duration of response (DoR): The length of time that a tumor continues to respond to treatment without the cancer growing or spreading.
  • Adverse event: Any unfavorable and unintended sign, symptom, or disease temporarily associated with the use of a medical treatment or procedure.
  • Metastatic: Cancer that has spread from its original site to other parts of the body.
  • Refractory: A disease that does not respond to treatment.
  • Relapsed: The return of a disease or the signs and symptoms of a disease after a period of improvement.
  • Neoadjuvant therapy: Treatment given before the main treatment, usually to shrink a tumor.
  • Adjuvant therapy: Treatment given after the main treatment to lower the risk of the cancer coming back.
  • Biomarker: A biological molecule found in blood, other body fluids, or tissues that is a sign of a normal or abnormal process, or of a condition or disease.
  • Circulating tumor DNA (ctDNA): Fragments of DNA from cancer cells found in the bloodstream.

References

  1. https://clinicaltrials.gov/study/NCT04879121
  2. https://clinicaltrials.gov/study/NCT03834961
  3. https://clinicaltrials.gov/study/NCT03213704
  4. https://clinicaltrials.gov/study/NCT02465060